21% Of AbbVie Inc (ABBV) Shareholders Want To Know How Drug Pricing Is Integrated Into Incentive Programs

At Friday’s annual shareholder meeting for pharma giant AbbVie Inc (NYSE:ABBV), a first-time shareholder proposal requesting regular reporting on how drug pricing risks are integrated into exec comp structures garnered over 21% support. Investor proponents from the Interfaith Center on Corporate Responsibility want to understand whether exec incentives are designed to reward short term gains generated by price hikes as opposed to longer term growth fueled by new product discoveries and other innovations.